Outlook on the Women’s Digital Health Global Market to 2027 – Featuring HeraMED, iSono Health and NURX Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Women’s Digital Health Market By Type, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021-2027” report has been added to ResearchAndMarkets.com’s offering.
The Global Women’s Digital Health Market size is expected to reach $4.7 billion by 2027, rising at a market growth of 18.5% CAGR during the forecast period.
Digital health can be defined as the utilization of information and communication technology in medicine and other health professions to manage illnesses and health risks, as well as to promote wellness. Comprehending digital health with women, Women’s digital health is a wide industry that includes a range of products, services, equipment, diagnostics, and software that cater to special female requirements such as reproductive health, fertility, and sexuality.
To build women’s digital health applications, many service providers are investigating artificial intelligence, machine learning, and the internet of things. Because it is envisioned to increase access to healthcare, reduce inefficiencies in the healthcare system, improve quality of treatment, minimize healthcare costs, and provide more individualized health care for patients, digital health has been gaining traction.
Smartphone adoption, preventive healthcare acceptance, favorable legislation, and more financing are all factors driving market expansion and awareness. According to data shared by the United Nations Department of Economic and Social Affairs in 2019, Women account for 49.6% of the world’s population that is a total of 3.905 billion. The rising incidence of chronic and infectious diseases among women is expected to boost the worldwide women’s digital health market’s overall development.
The increased frequency of women-centric disorders such as osteoporosis, breast cancer, and menopause, among others, are a few of the major reasons that are allowing women’s digital health-associated devices to establish a robust prevalence across the world. Breast cancer, for example, is the most common cancer among women, affecting 2.1 million women each year and accounting for almost 15% of all cancer deaths in women, according to the World Health Organization (WHO).
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic demolished a lot of major as well as minor industries. COVID-19 is one of the most hazardous pandemics that infected a majority of the world’s population. Since the onset of the COVID-19 from the Wuhan City of China, it scattered very rapidly in other parts of the world. To tackle the disruption caused by this virus, many governments have enforced stringent lockdown conditions which adversely impacted the global supply chains, negatively affecting manufacturing, product sales, and delivery schedules in the worldwide market.
In addition, during the pandemic, reproductive healthcare was designated as non-essential in various countries. As a result, digital fitness solutions such as smartphone apps and wearable tracking devices are expected to grow significantly in 2020. However, the manufacturing of devices associated with women’s digital health was significantly hindered due to the industrial closure.
Market Growth Factors:
Significant prevalence of women-centric diseases
Frequent outbreaks of diseases affecting women, such as anemia, osteoporosis, breast cancer, and menopause are a few of the most common diseases that, women all over the world are being diagnosed with. Along with being common, these diseases might be very critical for the patient. Due to the increasing occurrence of these diseases, it is now becoming a necessity to provide these patients with effective procurements. The demand for medications to treat these illnesses is constantly growing.
An increasing number of investment initiatives by established market players
One of the most noticeable trends in the women’s health devices market is the deployment of a number of investment initiatives, which is expected to contribute significantly to the market’s growth throughout the forecast period. This tremendous pace of investment projects has various advantages. The increased availability of more easy and economical solutions, which leads to wider adoption of these medical devices, is one of the benefits of these initiatives.
Marketing Restraining Factor:
Certain Women’s Healthcare Products Have Negative Side Effects
Despite the fact that women have a higher prevalence of life-threatening diseases than males, several factors are inhibiting the expansion of the women’s healthcare sector. One such factor is the negative effects of certain medicines on women’s health. Taking contraceptive tablets, for example, might cause spotting or bleeding between periods, sore breasts, nausea, headaches, and other unpleasant side effects. These side effects can be very painful as well as discomforting for them.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Mobile Apps
- Wearable Devices
- Diagnostic Tools
- Others
By Application
- Reproductive Health
- General Healthcare & Wellness
- Pregnancy & Nursing Care
- Pelvic Care
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
- HeraMED Ltd
- iSono Health, Inc.
- Clue by Biowink GmbH
- Chiaro Technology Ltd. (Elvie)
- Natural Cycles USA Corp
- Ava AG
- NURX, Inc.
- Athena Feminine Technologies, Inc.
- MobileODT Ltd.
- Lucina Health (Unified Women’s Healthcare)
For more information about this report visit https://www.researchandmarkets.com/r/92y77x
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
